Medicine and Dentistry
Neoplasm
100%
Nivolumab
100%
Glioblastoma
100%
Bevacizumab
100%
Patient
66%
Cells
62%
Arm
52%
T Cell Activation
50%
Autologous Tumor Cell
50%
Therapeutic Procedure
47%
Tumor Infiltrating Lymphocyte
44%
T Cell
25%
Clinical Trial
25%
Surgery
18%
Immunoglobulin G4
11%
Brain Tumor
11%
Survival
11%
Brain
6%
Clearance
6%
Analysis
6%
Blood Sampling
6%
Vasculotropin
6%
Cell Type
6%
Immunotherapy
6%
Immune System
6%
Immunocompetent Cell
6%
Flow Cytometry
6%
Combination Therapy
6%
CD39 Antigen
6%
Cytotoxicity
6%
Prognosis
6%
Quality of Life
5%
In Vitro
5%
Primary Tumor
5%
Exome Sequencing
5%
Tumor Biopsy
5%
Relapse
5%
Tissues
5%
Patient History of Surgery
5%
RNA
5%
Biopsy
5%
Culture
5%
Immunology and Microbiology
Nivolumab
100%
Bevacizumab
100%
Cells
56%
Arm
52%
Neoantigen
50%
Vaccine Efficacy
50%
Tumor Cell
50%
Tumor-Associated Macrophage
44%
Sample
23%
Brain
23%
Immunotherapy
18%
Immune Response
12%
Artificial Intelligence
12%
Time
12%
Immunoglobulin G4
11%
Intracellular Cytokine Staining
11%
Survival
11%
CD39 Antigen
6%
Immunity
6%
Mutation
6%
Clearance
6%
Vasculotropin
6%
Molecule
6%
Immune System
6%
Blood Sampling
6%
CD69
6%
Cytotoxicity
6%
Electric Potential
6%
Flow
6%
Immunity
6%
Color
6%
Immunocompetent Cell
6%
Cell Suspension
6%
Data Analysis
6%
Next Generation Sequencing
6%
Cytotoxic T-Cell
6%
Dose
6%
CD8
5%
Whole Exome Sequencing
5%
Life
5%
CD4
5%
Tissues
5%
